Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Lucid Group Nurtures Talent. Always.

Lockdown and Covid-19 have not stopped us from nurturing and developing the amazing talent we have at Lucid. Growth is at the heart of #LucidLife.So if you're looking for a place...

Lucid Group Communications Limited

- PMLiVE

Redx Pharma links up with Jazz Pharmaceuticals to develop targeted cancer drugs

Collaboration will focus on two cancer targets on the Ras/Raf/MAP kinase pathway

AstraZeneca AZ

AZ pauses COVID-19 vaccine study after participant falls ill

Serious adverse event puts clinical programme on hold

- PMLiVE

RedHill Biopharma’s SK2 inhibitor shows promise against coronavirus

Opaganib demonstrate potent inhibition of SARS-CoV-2 in an in vitro test

- PMLiVE

Top biopharma CEOs sign COVID-19 vaccine safety pledge

Leaders promise to uphold rigorous safety and efficacy protocols

- PMLiVE

Reflections of a Fireside Chat from the World Orphan Drug Congress 2020

Hear from Trish Shepherd COO, Patient & Brand Communications, OPEN Health

OPEN Health

- PMLiVE

First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India

Candidate uses similar technology from a licensed Hepatitis B vaccine

- PMLiVE

Sinovac’s COVID-19 vaccine appears safe in older adults

But immune responses were not as effective as those in younger adults

- PMLiVE

Positive COPD data for Synairgen’s SNG001 supports COVID-19 programme

UK biotech says data is encouraging for separate trial programme in COVID-19

OPEN Health has been awarded a Bronze Medal by EcoVadis

We are delighted to announce that OPEN Health has been awarded a Bronze Medal by EcoVadis for its very first Corporate Social Responsibility assessment in recognition of its commitment to Corporate Social...

OPEN Health

- PMLiVE

Widespread COVID-19 vaccinations not expected until mid-2021, says WHO

Potential candidates must prove robust efficacy and safety first

- PMLiVE

AbbVie signs immunotherapy pact with I-Mab worth $2bn

Focus of deal is anti-CD47 monoclonal antibody lemzoparlimab

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links